Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27594121 | 0.84 | PDE3B (0.41) | CYP3A4FAAHHRH1KDM4EMEN1 | |
| SCHEMBL7094583 | 0.80 | HRH1 (0.50) | HRH1CYP1A2 | |
| SCHEMBL6478654 | 0.76 | CYP2A6 (0.50) | CYP3A4HRH1KDM4EMEN1ALDH1A1 | |
| SCHEMBL22526771 | 0.75 | TPSAB1 (0.53) | TBXAS1HDAC1HDAC2HDAC3TBK1 | |
| SCHEMBL25944961 | 0.75 | HDAC2 (0.48) | HDAC1HDAC2HDAC8MEN1ALDH1A1 | |
| SCHEMBL612329 | 0.73 | HDAC6 (0.51) | TBXAS1HDAC1HDAC2HDAC3HDAC10 | |
| SCHEMBL10978490 | 0.73 | PDE3B (0.43) | CYP3A4FAAHKDM4EMEN1ALDH1A1 | |
| SCHEMBL1875583 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL611127 | 0.72 | HDAC6 (0.50) | TBXAS1HDAC1HDAC2HDAC3HDAC10 | |
| SCHEMBL16258540 | 0.72 | HDAC1 (0.50) | HDAC1HDAC2HDAC3TBK1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2018-04-26 | — | — | US | disclosed |
| WO-2016154369-A1 | COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-1187592-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1187592-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1315501-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1315501-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7153862-B2 | αv integrin receptor antagonists | MERCK & CO., INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-7056909-B2 | Alpha v integrin receptor antagonists | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050101593-A1 | Phosphoric acid salt of an integrin receptor antagonist | MEISSNER ROBERT S (US) | 2005-05-12 | — | — | US | disclosed |
| US-20040038963-A1 | Alpha v integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2004-02-26 | — | — | US | disclosed |
| US-6693101-B2 | ALKANOIC ACID DERIVATIVE; INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2004-02-17 | — | — | US | disclosed |
| US-20040019037-A1 | Alpha V integrin receptor antagonists | ASKEW BEN C (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1326615-A1 | PHOSPHORIC ACID SALT OF AN INTEGRIN RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6410526-B1 | BONE DISORDERS; RESTENOSIS; VISION DISORDERS; ANTICHOLESTEROL AGENTS; ANTICANCER, ANTITUMOR AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| WO-2002028395-A1 | PHOSPHORIC ACID SALT OF AN INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| US-20010053853-A1 | Alpha V integrin receptor antagonists | MERCK & CO., INC. | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038963-A1 | Alpha v integrin receptor antagonists | ITGAV, ADGRE5, ITGB3 | CYP3A4 3435/4885TBXAS1 932/4885HDAC1 1756/4885 |
| US-20180110762-A1 | Compositions Methods for Treating Chronic Kidney Disease | ITGAM, ITGAL, ITGB1 | CYP3A4 4884/4885TBXAS1 1378/4885HDAC1 1663/4885 |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | ITGAM, ITGB1, ITGB2 | CYP3A4 4884/4885TBXAS1 1947/4885HDAC1 1865/4885 |
| US-20040019037-A1 | Alpha V integrin receptor antagonists | ITGAV, ADGRE5, ITGA5 | CYP3A4 3769/4885TBXAS1 705/4885HDAC1 2093/4885 |
| US-20050101593-A1 | Phosphoric acid salt of an integrin receptor antagonist | ITGA5, ITGAL, ITGA2 | CYP3A4 4448/4885TBXAS1 855/4885HDAC1 2591/4885 |
| US-20010053853-A1 | Alpha V integrin receptor antagonists | ITGAV, ADGRE5, ITGA5 | CYP3A4 3769/4885TBXAS1 705/4885HDAC1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.